Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib

Objectives: Small cell transformation is a well-recognized mechanism of resistance to EGFR-TKI therapy in EGFR-mutant NSCLC, yet it remains a poorly-described phenomenon in ALK-rearranged NSCLC. Conclusions: Given the inevitable development of resistance in ALK + NSCLC, if feasible, re-biopsy on progression should be standard over liquid biopsy. Neuroendocrine carcinoma transformation remains an important mechanism of acquired resistance to lorlatinib. READ ARTICLE

Lung Cancer: 10.1016/j.lungcan.2019.05.025

Authors: Niamh Coleman, Andrew Wotherspoon, Nadia Yousaf, Sanjay Popat

Case StudyKirk SmithJune 6, 2019NSCLC, ALK positive, Oncogene addicted, Neuroendocrine transformation, Small cell lung cancer (SCLC)